Literature DB >> 22553722

Endogenous aspergillus endophthalmitis after kidney transplantation.

Huan-Huan Cheng1, Yong Ding, Min Wu, Cui-Cui Tang, Ri-Jia Zhang, Xiao-Feng Lin, Jin-Tang Xu.   

Abstract

Endogenous aspergillus endophthalmitis(EAE) after kidney transplant is a rare but important clinical problem due to potentially devastating consequences. Early diagnosis of EAE, timely removal of affected vitreous by vitrectomy, proper anti-fungal treatment, all contributed to the successful control of the disease. Therapeutic success of EAE in post-transplant patients depends largely on prompt diagnosis. Definite diagnosis of EAE is based on positive culture results of vitreous specimen, while fundoscopy and B scan ultrasound may aid early diagnosis. In terms of anti-fungal medicine, amphotericin B has long been the first choice, but its systemic applicaiton has severe adverse reactions, especially for patients with impaired renal function. Herein, we report the treatment modality of EAE after kidney transplant with vitrectomy, systemic administration of micafungin plus voriconazole, topical application of fluconazol and amphotercin B.

Entities:  

Keywords:  amphotercin B; aspergillus; endophthalmitis; kidney transplan-tation; micafungin

Year:  2011        PMID: 22553722      PMCID: PMC3340725          DOI: 10.3980/j.issn.2222-3959.2011.05.20

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN: 2222-3959            Impact factor:   1.779


  16 in total

1.  Histological examination of an eye with endogenous Aspergillus endophthalmitis treated with oral voriconazole: a case report.

Authors:  Shakhsanam E Aliyeva; Andrew J Ullmann; Ulrike B Kottler; Martine Frising; Oliver Schwenn
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-03-30       Impact factor: 3.117

2.  Successful treatment of Fusarium endophthalmitis with voriconazole and Aspergillus endophthalmitis with voriconazole plus caspofungin.

Authors:  Marlene L Durand; Ivana K Kim; Donald J D'Amico; John I Loewenstein; Ellis H Tobin; Shalom J Kieval; Stephen S Martin; Dimitri T Azar; Frederick S Miller; Brandon J Lujan; Joan W Miller
Journal:  Am J Ophthalmol       Date:  2005-09       Impact factor: 5.258

3.  The efficacy and tolerability of voriconazole in the treatment of chronic cavitary pulmonary aspergillosis.

Authors:  Lakshmi R Jain; David W Denning
Journal:  J Infect       Date:  2006-01-20       Impact factor: 6.072

4.  Endogenous Aspergillus endophthalmitis. Clinical features and treatment outcomes.

Authors:  P D Weishaar; H W Flynn; T G Murray; J L Davis; C C Barr; J G Gross; C E Mein; W C McLean; J H Killian
Journal:  Ophthalmology       Date:  1998-01       Impact factor: 12.079

Review 5.  Bacterial endophthalmitis: therapeutic challenges and host-pathogen interactions.

Authors:  Michelle C Callegan; Michael S Gilmore; Meredith Gregory; Raniyah T Ramadan; Brandt J Wiskur; Andrea L Moyer; Jonathan J Hunt; Billy D Novosad
Journal:  Prog Retin Eye Res       Date:  2007-01-22       Impact factor: 21.198

6.  Infectious complications after kidney transplantation: current epidemiology and associated risk factors.

Authors:  George J Alangaden; Rama Thyagarajan; Scott A Gruber; Katherina Morawski; James Garnick; Jose M El-Amm; Miguel S West; Dale H Sillix; Pranatharthi H Chandrasekar; Abdolreza Haririan
Journal:  Clin Transplant       Date:  2006 Jul-Aug       Impact factor: 2.863

7.  Aspergillus endophthalmitis: an unusual complication of disseminated infection in renal transplant patients.

Authors:  S Schelenz; D J A Goldsmith
Journal:  J Infect       Date:  2003-11       Impact factor: 6.072

8.  Combined action of micafungin, a new echinocandin, and human phagocytes for antifungal activity against Aspergillus fumigatus.

Authors:  Jung-Hyun Choi; Elmer Brummer; David A Stevens
Journal:  Microbes Infect       Date:  2004-04       Impact factor: 2.700

9.  Treatment of two postoperative endophthalmitis cases due to Aspergillus flavus and Scopulariopsis spp. with local and systemic antifungal therapy.

Authors:  Sayime Aydin; Bulent Ertugrul; Berna Gultekin; Guliz Uyar; Erkin Kir
Journal:  BMC Infect Dis       Date:  2007-07-31       Impact factor: 3.090

10.  Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis.

Authors:  David W Denning; Kieren A Marr; Wendi M Lau; David P Facklam; Voravit Ratanatharathorn; Cornelia Becker; Andrew J Ullmann; Nita L Seibel; Patricia M Flynn; Jo-Anne H van Burik; Donald N Buell; Thomas F Patterson
Journal:  J Infect       Date:  2006-05-06       Impact factor: 6.072

View more
  3 in total

1.  Endogenous endophthalmitis in patients with intravenous opioid use: demographics and associated comorbidities.

Authors:  Aditya Uppuluri; Marco A Zarbin; Neelakshi Bhagat
Journal:  Int Ophthalmol       Date:  2021-01-27       Impact factor: 2.031

2.  Risk factors for endophthalmitis requiring evisceration or enucleation.

Authors:  Xuehui Lu; Danny Siu-Chun Ng; Kangkeng Zheng; Kun Peng; Chuang Jin; Honghe Xia; Weiqi Chen; Haoyu Chen
Journal:  Sci Rep       Date:  2016-06-15       Impact factor: 4.379

3.  Endogenous endophthalmitis: diagnosis, management, and prognosis.

Authors:  Mohammad Ali Sadiq; Muhammad Hassan; Aniruddha Agarwal; Salman Sarwar; Shafak Toufeeq; Mohamed K Soliman; Mostafa Hanout; Yasir Jamal Sepah; Diana V Do; Quan Dong Nguyen
Journal:  J Ophthalmic Inflamm Infect       Date:  2015-11-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.